WE ARE AcuVox 🚨 Visit us: AcuVox.IO Oncology moves fast. The signal moves faster. AcuVox turns the noise from major congresses into real-time intelligence — the trials, data, and Colleague insights that actually matter. Most importantly... IT'S FREE for Colleagues!! Signals for #WCLC26 🫁already there! CHECK US OUT! 🧬 Less noise. More signal! Brought to you by @OncoAlert & @OncobitesTv

🚨 FDA Priority Review granted for durvalumab plus neoadjuvant enfortumab vedotin in muscle-invasive #BladderCancer : VOLGA Update Source: AstraZeneca The submission is supported by Phase III VOLGA results showing statistically significant and clinically meaningful improvements in event-free survival and overall survival. @DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @AlbigesL, @cdanicas, @amerseburger, @sonpavde, @DrDanielHeng, @declangmurphy, @seanmmcbride, @HHammersMD, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @scocmem, @ravikanesvaran, @AmandaNizamMD, @drenriquegrande, @BraunMDPhD, @EfstathiouEleni, @nataliagandur, @crisbergerot, @realbowtiedoc, @FernandoOnco, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @BRicciutiMD, @HHorinouchi, @UOzkerim, @p_ciracimd, @DrMirallas

What if a missed cancer diagnosis could cost you 8 years of life? 🚨 On this #WeekinOncology #Melanoma by OncoAlert🚨, our #OncoAlertAF colleagues Dr. Mario Balsa 🇪🇸 discusses an article out on Nature communications and how a melanoma study reveals the devastating long-term impact of false-negative diagnoses—and why getting the diagnosis right the first time matters. Would a 2-year diagnostic delay change the outcome? nature.com/articles/s41467-0… A large German 🇩🇪 study of 9,063 melanoma patients found that an initially false-negative cancer diagnosis can have serious long-term consequences. Among 206 patients with a missed diagnosis, the median delay to correct diagnosis was 24 months. Their 10-year recurrence-free and melanoma-specific survival were significantly lower than those diagnosed correctly. ✅️ Most strikingly, an initial false-negative diagnosis was associated with an average loss of 8.2 years of life, highlighting the critical importance of accurate and timely cancer detection. @TeresaSAmaral, @PAscierto, @JeffGershenwald, @jmkirkwood, @CelesteLebbe, @ProfGLongMIA, @jasonlukemd, @DWhitemanQIMRB, @pdnpdnpdn, @SaraGandini3 📣 Pinging our faculty: @nataliagandur, @realbowtiedoc, @FernandoOnco, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @BRicciutiMD, @HHorinouchi, @UOzkerim, @p_ciracimd, @AmandaNizamMD, @scocmem, @DrVilmaPBarcia, @DraMartinezLago, @DrMirallas, @GIMedOnc, @BettinaRyll 🎗️ Pinging our colleagues in melanoma: @DrBetofMDPhD, @FunchainMD, @CureMelanoma, @Melanoma_doctor, @HTawbi_MDPhD, @Chrystal_Paulos, @JaniceM10, @ProfGLongMIA, @ProfRAScolyer, @JeffGershenwald, @MelanomaAus, @AIMatMelanoma

How robust is AI in breast MRI when it leaves the institution it was trained on? ieeexplore.ieee.org/document… The MAMA-MIA Challenge: Advancing Generalizability and Fairness in Breast MRI Tumor Segmentation and Treatment Response Prediction The MAMA-MIA Challenge benchmarked AI 🤖 for breast MRI tumor segmentation and prediction of pathologic complete response using pre-treatment imaging. With 1,506 training patients and 574 external European test cases, 21 international teams were evaluated using standardized metrics, including subgroup consistency. ✅ Results revealed substantial variability and trade-offs between overall performance and subgroup fairness, highlighting the need for robust, generalizable, and equitable AI in clinical imaging. #BreastCancer @lidiagarrucho, @KaisarKushibar, @1richardobinna, @maciej_bobowicz

🧬 Could platinum chemotherapy have a larger role in genomically selected mCRPC? sciencedirect.com/science/ar… Carboplatin in patients with metastatic castration-resistant prostate cancer harboring somatic or germline homologous recombination repair gene mutations: phase II single-arm trial (CIPHER) This phase II study evaluated single-agent carboplatin in 39 men with HRR-altered metastatic castration-resistant #ProstateCancer previously treated with docetaxel and/or androgen receptor pathway inhibitors. ➡️ Carboplatin produced a confirmed PSA50 response in 41%, with a 32% objective response rate and median radiographic progression-free survival of 4.53 months. ➡️Responses appeared strongest in BRCA1/2-altered tumors. Although grade ≥3 adverse events occurred in 59%, quality of life was largely preserved. @DrRishabhOnco, @DrNikhilvasudev, @hema_oncologist, @dradhiparora, @aparna96, @RanjitKSMD, @brusabhanu1, @drsameerbakhshi, @batraatulonc @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

Pleased to share the randomized phase 2 ASPEN-06 study @NatureMedicine. Adding the CD47 blocker evorpacept with PTXRAM+Tras increased ORR in previously treated HER2+ gastric/GEJ cancer. Retained HER2 and high CD47 may enrich benefit.@OncoAlert @ASCO nature.com/articles/s41591-0…

FDA 🇺🇸 News: LITESPARK-011 Update in #kidneyCancer Source: FDA fda.gov/drugs/resources-info… On September 24, 2026, the FDA🇺🇸 approved belzutifan plus lenvatinib for adults with advanced renal cell carcinoma containing a clear cell component after PD-1/PD-L1 inhibitor treatment. In the LITESPARK-011 trial, the combination significantly improved progression-free survival and objective response rate versus cabozantinib, while overall survival was not statistically significant. ➡️ Median PFS was 14.6 versus 10.6 months, with response rates of 53% versus 40%. ➡️ Key safety concerns include anemia, hypoxia, cardiac dysfunction, hypertension, and embryo-fetal toxicity. @DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @AlbigesL, @cdanicas, @amerseburger, @sonpavde, @DrDanielHeng, @declangmurphy, @seanmmcbride, @HHammersMD, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @scocmem, @ravikanesvaran, @AmandaNizamMD, @drenriquegrande, @BraunMDPhD, @EfstathiouEleni, @nataliagandur, @crisbergerot, @realbowtiedoc, @FernandoOnco, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @BRicciutiMD, @HHorinouchi, @UOzkerim, @p_ciracimd, @AmandaNizamMD, @scocmem, @DrMirallas

🧬 BIF-1: linking autophagy & apoptosis across cancer? (Narrative review! link.springer.com/article/10…) ☝🏼↓ BIF-1 in melanoma (+ breast, prostate, CRC, bladder & gallbladder cancers) ▪️ Connects Beclin1–UVRAG–Vps34 autophagy with Bax/Bak-mediated apoptosis 🎯 Potential biomarker/therapeutic target, but clinical utility remains context-dependent… BIF-1 may be one factor worth interacting with 👀 @OncoAlert @OncoReporte @_SEOM @GrupoMelanoma

🧬 Not every CDKN2A variant behaves like “classic” CDKN2A (n=203 🇲🇽 ) ascopubs.org/doi/full/10.120… 💥 I49T carriers had markedly less melanoma vs known P/LP variants (OR 0.089; P<0.001) ☝🏼 Pancreatic cancer frequency was not significantly different (OR 0.45; P=0.17) 🤔 But pancreatic cancer appeared younger: 56 vs 71 years (P=0.026) Same gene, very different family portrait!!! @OncoAlert @OncoReporte @myESMO @_SEOM @GrupoMelanoma

Can a blood🩸 test detect cancer earlier—but still fail to demonstrate clinical utility? nejm.org/doi/full/10.1056/NE… @petersasieni, @PWMJohnson, @drlennardlee, @richarddneal, @CharlesSwanton Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis A large randomized English🇬🇧 trial involving 142,250 adults aged 50–77 evaluated annual multicancer early-detection blood testing alongside usual care. ➡️ After three screening rounds, there was no significant reduction in stage III/IV cancers compared with usual care alone (incidence rate ratio 1.03; P=.63). ➡️ Stage IV cancer incidence was lower with screening (IRR 0.86), although the result requires further follow-up. Trial-related adverse events were uncommon and nonserious. Pinging: @matteolambe, @aftimosp, @E_de_Azambuja, @DrSGraff, @ErikaHamilton9, @double_whammied, @maryam_lustberg, @raalbany, @hoperugo, @stolaney1, @LoiSher, @JaniceTNBCmets, @montypal, @DrDanielHeng, @apolo_andrea, @DrChoueiri, @PGrivasMDPhD, @TiansterZhang, @neerajaiims, @amerseburger, @sonpavde, @drenriquegrande, @tompowles1, @cdanicas, @nataliagandur, @realbowtiedoc, @Onco_Cifu88, @scocmem, @FernandoOnco, @ElisaAgostinett, @to_be_elizabeth, @Erman_Akkus, @MarioBalsaMD, @DrMirallas, @UOzkerim @UOzkerim, @PaulJiL, @DaisukeKotani, @DraMartinezLago, @p_ciracimd, @BenWestphalen, @CentralParkWMD, @graokane, @amandaNizamMD, @DrVilmaPBarcia

Five fractions, fewer bowel problems—but does ☢️ shorter treatment come with a trade-off in disease control? jamanetwork.com/journals/jam… Stereotactic Body Radiotherapy 🆚 Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer NRG-GU005, a phase 3 randomized trial of 698 men with localized intermediate-risk #ProstateCancer , compared 5️⃣ -fraction SBRT with moderately hypofractionated IMRT. ➡️ SBRT showed similar urinary quality-of-life outcomes, fewer bowel quality-of-life declines, and fewer severe genitourinary adverse events. However, SBRT did not improve disease-free survival: 3-year DFS was 88.6% versus 92.1% with MH-IMRT. ✅ The findings highlight an important trade-off between treatment convenience, toxicity, quality of life, and disease control. @PughStephanie, @jamesbyu, @felixfengmd, @cynthiaamenard, @jmmrad, @DrSpratticus, @abhiAsolanki, @DrHowardSandler, @NRGonc @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

What if blocking steroidogenesis upstream could overcome resistance in heavily pretreated prostate cancer? ejcancer.com/article/S0959-8… Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study ODM-209, an oral CYP11A1 inhibitor, blocks🚫 steroid hormone synthesis and was evaluated in a phase 1 trial involving heavily pretreated patients with metastatic castration-resistant #ProstateCancer and advanced #BreastCancer . ➡️Among mCRPC participants, 29% achieved a PSA50 response, rising to 47% among those with activating AR-LBD mutations. Partial responses occurred in 19%. ➡️Treatment-related adverse events reflected steroid depletion, including fatigue, edema, and adrenal insufficiency, supporting further investigation. @alicebernardt, @NaounNatacha

The @Uromigos score polls global experts about the clinical utility of various approaches in different disease settings. Each regimen is scored from 0 (should be avoided) to 3 (SOC) and mean results are presented. Here, @montypal discusses the latest results in front-line papillary RCC. @OncoAlert

FDA News: REFOCUS Update in #Cholangiocarcinoma On September 23, 2026, the FDA🇺🇸 approved lirafugratinib for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring FGFR2🧬 fusions or rearrangements. ➡️ In the REFOCUS trial of 116 patients, lirafugratinib achieved a 46% objective response rate and a median duration of response of 11.8 months. fda.gov/drugs/resources-info… @CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, @AndresC27622123, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara, @GaiaGriguolo, @scocmem

🏃‍♂️ Are we doing enough to make exercise part of supportive care for advanced prostate cancer? link.springer.com/article/10… Prevalence of meeting aerobic physical activity and resistance training guidelines in advanced prostate cancer: a descriptive study of racial and regional disparities in the IRONMAN💪 registry In 2,485 participants from the international IRONMAN registry, 58–63% met aerobic activity guidelines, but only 19–23% achieved recommended resistance training levels. Participation was particularly low in African 🌍 regions, where just 0–3% met resistance training guidelines. ➡️ Black participants and those from Africa had lower odds of meeting aerobic activity recommendations. ✅ The findings highlight important geographic and racial disparities and the need for tailored exercise strategies in advanced prostate cancer care. @Alekssolberg1, @nat_greaves, @Prof_IanD, @DrAndreFay, @DebEnting, @RayMcDermott1, @SimoneBadal, @APoopola, @JohnLazarus01, @quimmateo, @bjartell, @AOmlin, @camilleragin, @loreleimucci, @IRONMANregistry @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

I wonder how you would treat a patient after nephro-uretectomy for a high grade, T3N0M0 upper tract urothelial cancer. The tumor is PD-L1+ve and ctDNA-ve. The pateint is not eligible for cisplatin. @DrChoueiri @montypal @PGrivasMDPhD @OncoAlert @Annals_Oncology

The OncoAlert HORIZONS Series: Breast Cancer What happens when Watch & Wait fails? Therapeutic options after CDK4/6 inhibitor + endocrine therapy in HR+, HER2– advanced/metastatic Breast Cancer and emerging role of SERD-based combination strategies in this setting.

The OncoAlert HORIZONS Series: Breast Cancer What happens when Watch & Wait fails? How Mechanism based therapies are rewriting Cancer Care WATCH THE ENTIRE VIDEO HERE👉 piped.video/Efk2mf0RnNA?si=SXZ1… In this session, we explore: Therapeutic options after CDK4/6 inhibitor + endocrine therapy in HR+, HER2– advanced/metastatic #BreastCancer , and the emerging role of SERD-based combination strategies in this setting. 👩‍⚕️ Faculty: Dr. Sherene Loi @LoiSher Peter MacCallum Cancer Centre, Australia 🇦🇺 Dr. Elisa Agostinetto @ElisaAgostinett Institut Jules Bordet, Belgium 🇧🇪 The post-CDK4/6 inhibitor landscape in HR+/HER2– advanced breast cancer represents one of the most pressing unmet needs in oncology. While CDK4/6 inhibitors combined with endocrine therapy have firmly established themselves as the frontline standard, disease progression on this backbone remains nearly universal, driven by heterogeneous resistance mechanisms including ESR1 mutations, PI3K/AKT/mTOR pathway alterations, and RB1 loss. This biological diversity highlights the limitations of one-size-fits-all approaches. Next-generation oral selective estrogen receptor degraders (SERDs)—such as elacestrant, camizestrant, and imlunestrant—are reshaping the field. These agents achieve more complete estrogen receptor degradation than fulvestrant, show activity in ESR1-mutant disease, and are being actively evaluated in combination strategies with CDK4/6 and targeted therapies. Together, they are helping shift the post-CDK4/6 setting toward a more dynamic, biomarker-informed treatment paradigm. This OncoAlert Horizons educational series was supported by an unrestricted educational grant from Roche. All content was independently developed and fully controlled by the faculty. OncoAlert Horizons faculty: @LoiSher @JavierCortesMD @BarbaraPistill2 @BianchiniGP @ElisaAgostinett Sybille Loibl Rupert Barsch François-Clément Bidard Cristina Saura Pinging our #BreastCancer Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @nataliagandur @acampsmalea @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @Onco_Cifu88

🧠 What if the brain metastasis itself holds the key to identifying new treatment opportunities? Article esmoopen.com/article/S2059-7… Clinically actionable genomic alterations in breast cancer brain metastases Genomic 🧬 profiling of 56 #BrainCancer brain metastases (BCBMs) found ESCAT I/II actionable alterations in 76.8% of cases. HRR alterations involving BRCA1, BRCA2, or PALB2 occurred in 53.6%, with biallelic inactivation in 19.6%. PI3K/AKT/PTEN alterations were present in 48.2%. ➡️Among HER2-positive BCBMs, hotspot PIK3CA mutations were significantly associated with worse prognosis, highlighting potentially actionable genomic vulnerabilities and supporting further investigation of biomarker-driven treatment strategies. @GaiaGriguolo, @vitti10, @FedeMiglietta, @matteo_fassan, @apdeitos

🧬 Could PSMA PET/CT become more than a staging tool—and actually help us measure treatment response? Article 📰 sciencedirect.com/science/ar… PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review A systematic review of 11 studies evaluated PSMA PET/CT for treatment response assessment in hormone-sensitive #ProstateCancer . ➡️ ADT generally reduced PSMA expression, although an early flare was observed in a subset of lesions, particularly bone metastases. ➡️ Following radiotherapy ☢️ , PSMA reductions appeared greater when ADT was added. ✅ These findings suggest PSMA PET parameters could potentially help personalize treatment monitoring, but their association with long-term oncological outcomes remains to be established. @JennKa12, @MBauckneht, @ClaudiaKesch, @GGandaglia, @dr_rajwa, @Fabio_Zattoni, @AlbertoMartini_, @veerukasi, @Lara__Rodriguez, @fazekasMD, @TheGiesen, @m_martinamaggi, @CMercinelli, @miszczyk_marcin, @JGomezRivas, @ruimmbernardino, @alibourgi1_ali, @Tilki_De, @GMarra_MD, @EAU_YAUProstate @OncoAlert 🚨 #LPCCC27 @Silke_Gillessen @AOmlin @ProfKHerrmann @weoncologists

This week's OncoAlert 🚨 Newsletter is packed with practice-changing data: REGISTER TO GET IT 👉 buff.ly/N5gYtAc A 4-month survival jump just reset the #SCLC 🫁playbook📖 and MUCH MUCH MORE!!